Claire Leblanc1, Marguerite Baron1, Emilie Desselas1, Minh Hanh Phan1, Alexis Rybak1, Guillaume Thouvenin1,2, Clara Lauby1, Sabine Irtan3,4. 1. Department of Pediatric Pulmonology, APHP Hôpital Armand Trousseau, Paris, France. 2. UPMC Univ Paris 06, Centre de Recherche St Antoine Inserm UMRS.938, Sorbonne Universités, Paris, France. 3. UPMC Univ Paris 06, Centre de Recherche St Antoine Inserm UMRS.938, Sorbonne Universités, Paris, France. sabine.irtan@gmail.com. 4. Department of Pediatric Surgery, APHP Hôpital Armand Trousseau, 26 avenue du Dr Arnold Netter, 75012, Paris, France. sabine.irtan@gmail.com.
Abstract
Congenital pulmonary airway malformations or CPAM are rare developmental lung malformations, leading to cystic and/or adenomatous pulmonary areas. Nowadays, CPAM are diagnosed prenatally, improving the prenatal and immediate postnatal care and ultimately the knowledge on CPAM pathophysiology. CPAM natural evolution can lead to infections or malignancies, whose exact prevalence is still difficult to assess. The aim of this "state-of-the-art" review is to cover the recently published literature on CPAM management whether the pulmonary lesion was detected during pregnancy or after birth, the current indications of surgery or surveillance and finally its potential evolution to pleuro-pulmonary blastoma. CONCLUSION: Surgery remains the cornerstone treatment of symptomatic lesions but the postnatal management of asymptomatic CPAM remains controversial. There are pros and cons of surgical resection, as increasing rate of infections over time renders the surgery more difficult after months or years of evolution, as well as risk of malignancy, though exact incidence is still unknown. What is known: • Congenital pulmonary airway malformations (CPAM) are rare developmental lung malformations mainly antenatally diagnosed. • While the neonatal management of symptomatic CPAM is clear and includes prompt surgery, controversies remain for asymptomatic CPAM due to risk of infections and malignancies. What is new: • Increased rate of infection over time renders the surgery more difficult after months or years of evolution and pushes for recommendation of early elective surgery. • New molecular or pathological pathways may help in the distinction of type 4 CPAM from type I pleuropulmonary blastoma.
Congenital pulmonary airway malformations or CPAM are rare developmental lung malformations, leading to cystic and/or adenomatous pulmonary areas. Nowadays, CPAM are diagnosed prenatally, improving the prenatal and immediate postnatal care and ultimately the knowledge on CPAM pathophysiology. CPAM natural evolution can lead to infections or malignancies, whose exact prevalence is still difficult to assess. The aim of this "state-of-the-art" review is to cover the recently published literature on CPAM management whether the pulmonary lesion was detected during pregnancy or after birth, the current indications of surgery or surveillance and finally its potential evolution to pleuro-pulmonary blastoma. CONCLUSION: Surgery remains the cornerstone treatment of symptomatic lesions but the postnatal management of asymptomatic CPAM remains controversial. There are pros and cons of surgical resection, as increasing rate of infections over time renders the surgery more difficult after months or years of evolution, as well as risk of malignancy, though exact incidence is still unknown. What is known: • Congenital pulmonary airway malformations (CPAM) are rare developmental lung malformations mainly antenatally diagnosed. • While the neonatal management of symptomatic CPAM is clear and includes prompt surgery, controversies remain for asymptomatic CPAM due to risk of infections and malignancies. What is new: • Increased rate of infection over time renders the surgery more difficult after months or years of evolution and pushes for recommendation of early elective surgery. • New molecular or pathological pathways may help in the distinction of type 4 CPAM from type I pleuropulmonary blastoma.
Entities:
Keywords:
CPAM; Pleuropulmonary blastoma; State of the art
Authors: Zeena Makhija; Christopher R Moir; Mark S Allen; Stephen D Cassivi; Claude Deschamps; Francis C Nichols; Dennis A Wigle; K Robert Shen Journal: Ann Thorac Surg Date: 2011-03-21 Impact factor: 4.330
Authors: Steven S Rothenberg; William Middlesworth; Angela Kadennhe-Chiweshe; Gudrun Aspelund; Keith Kuenzler; Robert Cowles; Lawrence Bodenstein; Saundra Kay; Kristin Shipman; Cathryn Rothenberg; Charles Stolar; Steven Stylianos Journal: J Laparoendosc Adv Surg Tech A Date: 2015-01-05 Impact factor: 1.878
Authors: Shaun M Kunisaki; Stacey Ehrenberg-Buchner; Jonathan R Dillman; Ethan A Smith; George B Mychaliska; Marjorie C Treadwell Journal: J Pediatr Surg Date: 2015-03-14 Impact factor: 2.545
Authors: Timothy M Crombleholme; Beverly Coleman; Holly Hedrick; Kenneth Liechty; Lori Howell; Alan W Flake; Mark Johnson; N Scott Adzick Journal: J Pediatr Surg Date: 2002-03 Impact factor: 2.545
Authors: Maryann V Volpe; Eunice Chung; Jason P Ulm; Brian F Gilchrist; Steven Ralston; Karen T Wang; Heber C Nielsen Journal: Am J Physiol Lung Cell Mol Physiol Date: 2009-05-01 Impact factor: 5.464
Authors: Joshua K Ochieng; Kim Schilders; Heleen Kool; Anne Boerema-De Munck; Marjon Buscop-Van Kempen; Cristina Gontan; Ron Smits; Frank G Grosveld; Rene M H Wijnen; Dick Tibboel; Robbert J Rottier Journal: Am J Respir Cell Mol Biol Date: 2014-08 Impact factor: 6.914
Authors: Simone de Campos Vieira Abib; Chan Hon Chui; Sharon Cox; Abdelhafeez H Abdelhafeez; Israel Fernandez-Pineda; Ahmed Elgendy; Jonathan Karpelowsky; Pablo Lobos; Marc Wijnen; Jörg Fuchs; Andrea Hayes; Justin T Gerstle Journal: Ecancermedicalscience Date: 2022-02-17
Authors: Mario Lima; Simone D'Antonio; Neil Di Salvo; Giovanni Parente; Beatrice Randi; Michele Libri; Tommaso Gargano; Giovanni Ruggeri; Vincenzo Davide Catania Journal: J Indian Assoc Pediatr Surg Date: 2021-05-17